Evenamide Hydrochloride

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the approval for its pivotal ENIGMA-TRS Phase III development program evaluating evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). Newron today announced the approval for its pivotal ENIGMA-TRS Phase III development program evaluating evenamide as an add-on therapy to current antipsychotics, including clozapine, in patients with treatment-resistant schizophrenia (TRS). The ENIGMA-TRS Phase III development program consists of two pivotal studies, ENIGMA-TRS 1 and ENIGMA-TRS 2. The two studies are expected to meet the ICH (International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) specified regulatory requirements for submission of the registration dossier for evenamide in major territories, including the US and Europe. ENIGMA-TRS 1 is an international, 52-week, randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation anti-psychotics (SGAs), including clozapine, will meet Treatment Response and Resistance Psychosis (TRRIP) international consensus criteria for TRS. ENIGMA-TRS 1 will enroll at least 600 patients at study centers in Europe, Asia, Latin America and Canada. Patients will undergo a 42-day screening period, during which their TRS diagnosis, antipsychotic plasma levels (background medication), and conformance to protocol selection criteria will be evaluated by an Independent Eligibility Assessment Committee (IEAC) of three leading international schizophrenia experts. The primary assessment of efficacy and safety will be performed 12 weeks after randomization to treatment. The study will continue double-blind and placebo-controlled until the 52-week (i.e. one year) time point. Enrolment to the study will start imminently. The 12-week results from the study are expected in Q4 2026. ENIGMA-TRS 2, approved by the US Food and Drug Administration (FDA), will be performed at centers in the US and selected additional countries and will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase III study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide. Patients will meet selection criteria and be reviewed by the above-mentioned IEAC. The analysis for determination of efficacy and safety will be performed after patients complete 12 weeks of participation in the trial. US investigational centers are expected to initiate the study within the next three months. Stephen Marder, MD, Distinguished Professor of Psychiatry, Semel Institute of Neuroscience & Human Behavior, and Director, Section on Psychosis, UCLA Neuropsychiatric Institute, commented: “The imminent initiation of ENIGMA-TRS 1 study of evenamide is a significant milestone in the search for new medications to treat this devastating condition. Evenamide’s modulation of glutamate, good tolerability, and efficacy in studies performed to date, both in patients who are poor responders or treatment resistant to SGAs, suggests its therapeutic potential in patients with TRS. The field eagerly looks forward for results from this landmark trial.” Jean-Pierre Lindenmayer, MD, Director of Research, Psychopharmacology Research Unit - Nathan Kline Institute for Psychiatric Research at Manhattan Psychiatric Center, added: “Evenamide’s selectivity for sodium channels and consequent modulation of glutamate, the demonstration of its efficacy in multiple animal models of psychosis as well as the MAM model of neurodevelopmental abnormalities, suggests promising results in patients with TRS. Completed studies in inadequate responders to SGAs and the results of a one-year study in patients with TRS predict therapeutic benefit of evenamide in TRS patients. Evenamide has the potential to fill a wide gap in our treatment for patients with incomplete response to SGAs, including clozapine. I look forward to participating to the ENIGMA-TRS 2 trial as a study center.” Ravi Anand, MD, Chief Medical Officer of Newron, stated: “Newron greatly appreciates the regulatory approval of the ENIGMA-TRS trials. The positive results of evenamide observed in clinical studies and demonstrated in disease models have led to high enthusiasm in investigators to participate in this landmark program.” The Phase III ENIGMA-TRS clinical trials are part of Newron’s development program for evenamide, targeting patients with schizophrenia experiencing worsening of psychosis on therapeutic doses of current antipsychotics, as well as treatment-resistant patients, which together account for the vast majority of patients suffering from schizophrenia. Results from previous Phase II (study 014/015) and Phase III (study 008A) studies have demonstrated evenamide’s significant and increasing efficacy as an add-on therapy on multiple measures of psychopathology in patients with TRS and inadequate responders, respectively. These results also confirmed a favorable safety and tolerability profile, adding to the growing evidence that evenamide’s glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments. Newron has entered into licensing agreements with EA Pharma, a subsidiary of Eisai, in Japan and other designated territories, and with Myung In Pharm in South Korea, to develop, manufacture and commercialize evenamide in the respective territories. Under the terms of the agreements, Newron will receive up to a maximum total of EUR 117 million, including an upfront payment of EUR 44 million, financial contributions to the Phase III ENIGMA-TRS program, milestone payments, and tiered royalties up to a double-digit percentage of net sales for evenamide, from EA Pharma; Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron’s upcoming Phase III ENIGMA-TRS trial and cover the costs related to this population. Newron is actively exploring additional partnerships for the global development and commercialization of evenamide. About schizophrenia Approximately 25 million people worldwide are affected by schizophrenia. Despite more than 60 different types of atypical and typical antipsychotics used to treat schizophrenia globally, a considerable number of patients remain severely ill or resistant to treatment. Overall, 30-50% of patients do not respond to the available medications and are defined as treatment resistant. In addition to the patients with treatment-resistant schizophrenia (TRS), another 20-30% are described as “poor responders to anti-psychotic medication”, even if not meeting the criteria for TRS. New findings indicate that patients with TRS have abnormalities in the glutamatergic system, but not in dopaminergic transmission, so there is a significant unmet medical need for treatments with a glutamatergic mechanism of action, efficacious both in TRS patients and in those who are poor responders to the current treatments. About evenamide Evenamide is the first new chemical entity that has demonstrated significant benefits in this difficult-to-treat patient population, as seen in the potentially pivotal Phase III study 008A trial, as an add-on treatment to second generation anti-psychotics including clozapine, in 291 poorly responding patients with chronic schizophrenia. The primary endpoint, the Positive and Negative Syndrome Scale (PANSS)1, and the key secondary endpoint, the Clinical Global Impressions Scale – Severity (CGI-S), were met and showed statistical significance compared to placebo. Importantly, evenamide treatment was associated with statistically significant increases in the proportion of patients who experienced “clinically meaningful benefit” on the outcome variables. Evenamide was extremely well tolerated, without any of the usual side effects of available anti-psychotics. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: www.newron.com Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. ______________________________ 1 Positive and Negative Syndrome Scale (PANSS) is widely used in clinical trials of schizophrenia and is considered the “gold standard” for assessment of antipsychotic treatment efficacy (Innvo Clin Neurosci, 2017: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788255/)

MILAN--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2024, and provided an outlook for 2025. Highlights 2024: Evenamide Exceptional data from study 014/015 and study 008A: Demonstrated significant and increasing efficacy of evenamide as an add-on therapy on multiple measures of psychopathology in treatment-resistant schizophrenia (TRS) and chronic schizophrenia Confirmed evenamide’s favorable safety and tolerability profile The data adds to the growing evidence that evenamide’s glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who are not benefiting from current antipsychotic treatments on the market Strategic licensing and partnerships: In December 2024, the Company announced a licensing agreement with EA Pharma, a subsidiary of Eisai, to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories. Under the terms of the agreement, Newron will receive up to a maximum total of EUR 117 million, including an upfront payment of EUR 44 million, financial contributions to its upcoming pivotal Phase III one-year study of evenamide, milestone payments, and tiered royalties up to a double-digit percentage of net sales for evenamide Post-period, in January 2025, the Company announced a further licensing agreement with Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea. Under the terms of the agreement, Myung In Pharm will contribute 10% of the total patient population to be enrolled into Newron’s upcoming Phase III trial and cover the costs related to this population Upcoming milestones: Newron is planning to initiate a pivotal Phase III randomized, double-blind, one-year trial in Q2 2025 that will compare evenamide to placebo as an add-on treatment in patients with TRS The Company continues to pursue further development opportunities for evenamide in other territories Corporate Post-period, in March 2025, the Board of Directors of Newron proposed Dr. Chris Martin for election as Independent, Non-Executive Director and Chairman of the Board of Directors, at the Company’s upcoming Annual General Meeting, to be held on April 23, 2025. He is expected to succeed Dr. Ulrich Köstlin, who will end his twelve years of service on the Board of Newron following the completion of this year’s shareholder meeting Newron’s Board was strengthened in April 2024 through the appointment of Margarita Chavez as an Independent, Non-Executive Director and Chair of the Board’s Business Development Committee, bringing more than 20 years of US and international dealmaking expertise and leadership in the pharmaceutical industry In March 2024, the Company signed an agreement for the subscription of up to 2.05 million newly issued shares with an institutional investor focused on investing in high-growth firms across sectors including biotech and healthcare, with total proceeds generated of EUR 15 million Also in March 2024, an agreement with the European Investment Bank was reached to extend the near-term tranche repayment dates of its 2018 financing agreement until the end of 2025 and into 2026 Stefan Weber, CEO of Newron, commented: “The positive evenamide data and strong momentum from our partnering agreements have set the stage for our pivotal Phase III randomized, double-blind, one-year trial, that will compare evenamide to placebo as an add-on treatment in at least 600 patients with TRS. We expect to continue building on our progress in 2025 by initiating this clinical trial with the compound in Q2 2025, and pursuing further development opportunities for evenamide, in addition to the two licensing agreements announced to date. A key objective for 2025 will also be strengthening our institutional shareholder base, and the preparation of a potential registration of our shares in the USA, the key capital market for our industry. Newron’s total available cash resources, along with the proceeds deriving from the two licensing agreements for evenamide – signed with EA Pharma/Eisai Group in late December 2024 and with Myung In Pharm in early January 2025 – will fund the Company’s planned development programs and operations well through 2026.” “We encourage our shareholders to register for and participate in the upcoming Ordinary and Extraordinary shareholders’ meeting on April 23, 2025, as the proposed resolutions will materially contribute to the success of our ambitions. At these meetings, we will also bid a heartfelt farewell to Ulrich Köstlin and thank him for his many years of service as Newron's Chairman,” Stefan Weber added. Evenamide – advancing schizophrenia treatment 2024 was marked by significant milestones for the evenamide development program, with Newron reporting two sets of exceptional data on the use of evenamide as an add-on treatment for patients with TRS and chronic schizophrenia, as well as announcing its first licensing agreement: In January, the Company reported the final one-year results from study 014/015, a Phase II open label trial evaluating evenamide as an add-on therapy to a single antipsychotic in TRS patients. The data demonstrated that evenamide as an add-on treatment for patients with TRS was associated with sustained, clinically significant benefits that increased throughout the one-year course of treatment, with more than 70% of patients experiencing a clinically important reduction in disease severity. Remarkably, 25% of patients achieved “remission”, which represents the highest level of improvements that can be obtained in a patient with schizophrenia and has never been described before in TRS patients. Furthermore, approximately 50% of patients that completed one-year of treatment with evenamide no longer met the criteria used to diagnose treatment resistance; also, there were no patient relapses during the one-year treatment period. In April, Newron announced data from study 008A, a potentially pivotal four-week, randomized, double-blind and placebo-controlled Phase III study of evenamide as an add-on therapy in patients with chronic schizophrenia demonstrating inadequate benefit from their current second-generation antipsychotic. The study met its key safety and efficacy endpoints: the primary endpoint (improvement of the Positive and Negative Syndrome Scale PANSS Total Score) and key secondary endpoint (improvement of the Clinical Global Impression of Severity CGI-S), with a 96% rate of study completion. Additionally, no new or specific concerns were raised in the study. In May, further analysis of this data revealed significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings, confirming a highly statistically significant improvement for evenamide irrespective of the population analyzed or the statistical methods used. In addition, the benefits noted on efficacy measures continued to increase up to day 29, indicating potentially larger and more enduring effects following long-term treatment with evenamide. Together, the data from these studies reaffirmed evenamide’s favorable safety and tolerability profile and demonstrated its efficacy on multiple measures of psychopathology in TRS and chronic schizophrenia. The readouts also add to the growing evidence that the glutamatergic inhibition mechanism of action offers an innovative therapeutic option to schizophrenia patients who do not benefit from current antipsychotic treatments. Financial key takeaways 2024: In 2024, Newron reported, for the first time since its inception, a net profit of EUR 15.8 million, compared with a net loss of EUR 16.2 million in 2023 License income in 2024 was EUR 44.5 million, predominantly resulting from the upfront payment due under the license agreement signed with EA Pharma/Eisai Group In addition, the Company received royalty payments for Xadago from Zambon of EUR 6.9 million (2023: EUR 6.7 million) Total revenues increased from EUR 9.1 million in 2023 to EUR 51.4 million in the reporting period Newron's R&D expenses increased to EUR 13.6 million (2024) from EUR 13.2 million in 2023 G&A expenses increased from EUR 7.5 million in 2023 to EUR 11.5 million in 2024, mostly due to one-time transaction-related costs As the upfront payment was transferred in January 2025, only, the cash used in operating activities increased to EUR 17.6 million in 2024, from EUR 10.1 million in 2023 Cash and other current financial assets as of December 31, 2024, were at EUR 9.8 million, compared to EUR 12.6 million at the beginning of the year. EUR 42 million of proceeds from the execution of the two licensing agreements with EA Pharma/Eisai Group and Myung In Pharm were collected net of withholding taxes, in January 2025. Financial Summary (IFRS) 2024 and 2023: In thousand EUR (except per share information) 2024 2023 License income from contracts with customers 44,470 58 Royalties from contracts with customers 6,920 6,735 Other income from contracts with customers 0 2,264 Revenue 51,390 9,057 Research and development expenses (13,642) (13,152) Operating Result 26,173 (11,629) Financial result, net (4,779) (4,571) Net gain/(loss) 15,843 (16,224) Gain/(Loss) per share 0.85 (0.91) Cash used in operating activities (17,614) (10,140) Cash, cash equivalents and Other current financial assets 9,826 12,599 Total assets 63,908 25,866 Newron’s Annual Report 2024 is available for download on the Company’s website at: www.newron.com/investors/reports-and-presentation/year/2024 Outlook 2025: Newron’s position has been strengthened in 2024 and early 2025 with licensing agreements and increased financial flexibility. Following a busy 2024 full of milestones for our evenamide development program, Newron expects to continue building on its progress in 2025 by initiating the pivotal Phase III clinical study of the compound in Q2 2025, and pursuing further development opportunities for evenamide in addition to the two licensing agreements announced to date. Newron is delighted with the progress of evenamide so far and is excited about the clear benefits that the development compound can bring to patients who are underserved by the antipsychotics currently on the market, and who are in great need of new and innovative treatments. The Company looks forward to providing an update on evenamide, including any business development opportunities, in due course. A key objective for 2025 will be strengthening the Company’s institutional shareholder base and the preparation of a potential registration of its shares in the USA, the key capital market for the Life Sciences industry. The Company’s total available cash resources together with the proceeds deriving from the signature of the two licensing agreements for evenamide with EA Pharma/Eisai Group in late December 2024 and with Myung In Pharm in early January 2025 are expected to fund Newron’s planned development programs and operations well through 2026. Media/analyst/investor Conference Call today at 3 pm CET/2 pm UK/9 am ET Newron’s management team will today present the 2024 full-year results and provide an update and guidance for 2025. Please dial in five to ten minutes prior to the beginning of the call using one of the following telephone numbers: Switzerland/Europe: +41 (0)58 310 50 00 United Kingdom: +44 (0)207 107 0613 United States: +1 (1)631 570 5613 For additional available numbers, please see here The presentation is available at www.newron.com/investors/reports-and-presentation/year/2024 2025 Shareholders’ Meeting Agenda: Newron’s Board of Directors has approved the below agenda for the April 23, 2025, Shareholders’ Ordinary and Extraordinary annual meeting, which will take place at the Company’s registered office (Via Antonio Meucci 3) in Bresso (Mi), Italy, starting at 10 am CET. The formal invitation to shareholders will be issued and disclosed in the statutory papers on or around April 1, 2025. All documents connected with the agendas as per applicable laws and regulations as well as the necessary information to register and attend these meetings will be made available on the Company’s website (www.newron.com/investors/shareholders-meeting) on the same day. The agenda is as follows: Ordinary part 1. Review and approval of the annual financial statements and presentation of the consolidated financial statements as of December 31, 2024. Connected and consequent resolutions; 2. Appointment of a new member of the Board of Directors, until the approval of the financial statements as of December 31st, 2025, as follows: 2.1 Proposal to appoint Chris Martin* in quality of new independent and non-executive director; 2.2 Proposal to appoint Chris Martin in quality of new non-executive Chairman of the Board; 2.3 Determination of the remuneration. Connected and consequent resolutions: 3. Appointment of the auditing company for the three fiscal-year term 2025-2027; connected and consequent resolutions; 4. Appointment of the statutory auditors for the three fiscal-year term 2025-2027 and determination of their fees. Connected and consequent resolutions; Extraordinary part 1. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 399,177.00, in addition to any premium, without option rights, pursuant to art. 2441, paragraph 4, second part of the Civil Code. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 2. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 119,753.00, in addition to any premium, with exclusion of the option rights, pursuant to art. 2441, paragraphs 5, 6 and/or 8 of the Civil Code, for one or more stock option plans. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 3. Proposal of attribution to the Board of Directors of powers, pursuant to art. 2443 and 2420-ter of the Civil Code, to be executed during the next 5 years, to increase the share capital, in one or more times, for a maximum amount of nominal Euro 1,397,120.00, in addition to any premium, by issuing shares and/or convertible bonds, with or without option rights, pursuant to art. 2441, paragraphs 4, first part, 5, 6 and/or 8 of the Civil Code, optionally cum warrant, optionally related to the listing of the shares or the other above mentioned instruments on NASDAQ and/or NYSE and/or on any other market. Amendment of art. 6 of Newron By-law. Related and consequential resolutions; 4. Creation of American Depositary Shares and listing them on the NASDAQ and/or NYSE and/or on any other market in the United States of America; connected and consequent resolutions * Dr. Chris Martin is a recognized leader in the biopharma industry who has taken therapeutic technology from the lab bench through to regulatory approval and global market sales. Over his career, he has raised more than $1.4 billion on the capital markets to support the development of his companies. He was instrumental in co-founding ADC Therapeutics in 2012 and served as its CEO from its inception until 2022. Under his tenure, the Swiss-based ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange listed leader in the field of antibody-drug conjugates (ADC) with products marketed worldwide. He co-founded and was the CEO of Spirogen Ltd, an innovator of ADC payload technology, which was subsequently sold to AstraZeneca for a total of up to $440 million. Currently chairing the boards of MyricxBio, Tagworks, Tokamak Energy Ltd. and serving on the boards of Osivax SAS, Solcom Ltd. and Senya therapeutics (all private companies), Chris Martin holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School. He is a British citizen and lives in Switzerland. Financial calendar AGM and EGM 2025: April 23, 2025 Half-year results and report 2025: September 16, 2025 About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson’s disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: www.newron.com Important Notices This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.